Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Ogasawara A, et al. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):631. doi: 10.1007/s00259-022-06050-x. Eur J Nucl Med Mol Imaging. 2023. PMID: 36427067 No abstract available.
Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies.
Yadav R, Sukumaran S, Zabka TS, Li J, Oldendorp A, Morrow G, Reyes A, Cheu M, Li J, Wallin JJ, Tsai S, Sun L, Wang P, Ellerman D, Spiess C, Polson A, Stefanich EG, Kamath AV, Ovacik MA. Yadav R, et al. Among authors: zabka ts. Pharmaceutics. 2022 Apr 30;14(5):970. doi: 10.3390/pharmaceutics14050970. Pharmaceutics. 2022. PMID: 35631556 Free PMC article.
Establishment of baseline profiles of 50 bile acids in preclinical toxicity species: A comprehensive assessment of translational differences and study design considerations for biomarker development.
Sangaraju D, Katavolos P, Liang X, Chou C, Zabka TS, Dean B, Maher J. Sangaraju D, et al. Among authors: zabka ts. Toxicol Appl Pharmacol. 2022 May 15;443:116008. doi: 10.1016/j.taap.2022.116008. Epub 2022 Apr 1. Toxicol Appl Pharmacol. 2022. PMID: 35378153
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.
Rossman P, Zabka TS, Ruple A, Tuerck D, Ramos-Vara JA, Liu L, Mohallem R, Merchant M, Franco J, Fulkerson CM, Bhide KP, Breen M, Aryal UK, Murray E, Dybdal N, Utturkar SM, Fourez LM, Enstrom AW, Dhawan D, Knapp DW. Rossman P, et al. Among authors: zabka ts. Mol Cancer Ther. 2021 Nov;20(11):2177-2188. doi: 10.1158/1535-7163.MCT-20-0893. Epub 2021 Aug 25. Mol Cancer Ther. 2021. PMID: 34433660 Clinical Trial.
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week.
Januzzi JL Jr, Canty JM, Das S, DeFilippi CR, Gintant GA, Gutstein DE, Jaffe A, Kaushik EP, Leptak C, Mehta C, Pina I, Povsic TJ, Rambaran C, Rhyne RF, Salas M, Shi VC, Udell JA, Unger EF, Zabka TS, Seltzer JH. Januzzi JL Jr, et al. Among authors: zabka ts. J Am Coll Cardiol. 2021 Apr 20;77(15):1922-1933. doi: 10.1016/j.jacc.2021.02.040. J Am Coll Cardiol. 2021. PMID: 33858628 Free article. Review.
47 results